A New Hope for Patients with
Chronic and Serious Neurologically
Mediated Conditions
Trevi Therapeutics, founded in Connecticut
in 2011, is based in New Haven and
employs several talented and experienced
physicians, scientists, clinical operations
staff and the support team. We are a drug
development company that focuses on
developing treatments with the potential
to signifi cantly improve the quality of life
of patients suffering from the serious
symptoms associated with chronic
neurologically mediated conditions.
Trevi is currently developing nalbuphine
ER for the treatment of chronic pruritus,
chronic cough in patients with idiopathic
pulmonary fi brosis and levodopa-induced
dyskinesia in patients with Parkinson's
disease. These conditions share a common
pathophysiology that is mediated through opioid receptors in the central and peripheral
nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine
ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo
nodularis. If you, or somebody you know, suffers severe pruritus in prurigo nodularis, and
you are interested in participating in a clinical trial, see the trial information and contact
details below.
Clintrials.gov: NCT03497975
Contact: Paula Buckley
+1 203 304-2499
paula.buckley@trevitherapeutics.com
Dr. Helena Brett Smith
+1 203 304 2499
helena.brett-smith@trevitherapeutics.com
195 Church Street, 14th Floor, New Haven, CT
TreviTherapeutics.com
